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http://dx.dLack of Antidonor Alloantibody Does Not Indicate Lack
of Immune Sensitization: Studies of Graft Loss in
a Haploidentical Hematopoietic Cell Transplantation
Swine Model
Raimon Duran-Struuck,1 Abraham Matar,1 Rebecca Crepeau,1 Ashley Gusha,1
Marian Schenk,1 Isabel Hanekamp,1 Vimukthi Pathiraja,1
Thomas R. Spitzer,2 David H. Sachs,1 Christene A. Huang1Loss of chimerism is an undesirable outcome of allogeneic hematopoietic cell transplantation (HCT) after
reduced-intensity conditioning. Understanding the nature of cellular and humoral immune responses to
HCTafter graft loss could lead to improved retransplantation strategies. We investigated the immunologic
responses after graft loss in miniature swine recipients of haploidentical HCT that received reduced-intensity
conditioning. After the loss of peripheral blood chimerism, antidonor cellular responses were present with-
out detectable antidonor antibody. Reexposure to donor hematopoietic cells after graft loss induced a sen-
sitized antidonor cellular response. No induced antidonor antibody response could be detected despite
evidence of cellular sensitization to donor cells. In contrast, unconditioned animals exposed repeatedly to
similar doses of haploidentical donor cells developed antidonor antibody responses. These results could
have important implications for the design of treatment strategies to overcome antidonor responses in
HCTand improve the outcome of retransplantation after graft loss.
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Reduced-intensity conditioning (RIC) regimens
have facilitated hematopoietic cell transplantation
(HCT) in patients who previously would not have
been considered suitable candidates, owing to the
toxicity of myeloablative preparatory regimens [1]. Al-
though the risk of complications related to condition-
ing is decreased with RIC, the risk of graft loss is
increased. Graft loss, whether secondary to rejection,
the inability of the stem cells to engraft due to the
lack of ‘‘space’’ [2], or poor graft quality [3], can have
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tive immunologic process in which donor cells sensi-
tize the host (through cellular and/or humoral
mechanisms). Conversely, if the loss of donor cells is
not immunologic but rather related to a deficiency in
stem cell ‘‘fitness’’ or quality [3], there may be no im-
munologic consequences (eg, sensitization). Factors
related to graft loss include donor–recipient MHC
mismatch, degree of host myeloablation, level of im-
munosuppression post-HCT, degree of host immuno-
competence related to immediate preparatory
regimens, level of T cell depletion of the donor graft,
and presensitization to donor antigens, as is seen in pa-
tients with aplastic anemia [4-6]. To date, few clinical
studies have assessed immune responses of patients af-
ter graft loss and reexposure of donor antigen.
In this study, we investigated the immunologic re-
sponses after graft loss in the Massachusetts General
Hospital MHC-defined miniature swine, a clinically
relevant large-animal model of HCT [7]. Recipients
underwent RIC and received cytokine-mobilized pe-
ripheral blood mononuclear cells (PBMCs) haplomis-
matched at both MHC I and MHC II. The RIC
regimen consisted of CD3 immunotoxin, 100 cGy of
total body irradiation (TBI), and 45 days of cyclospor-
ine A (referred to as the ‘‘ITC’’ regimen hereinafter).1629
1630 Biol Blood Marrow Transplant 18:1629-1637, 2012R. Duran-Struuck et al.Seventeen ITC-conditioned haplo-HCT recipients
were engrafted with donor stem cells and maintained
moderate to high (30%-70%) donor-derived chime-
rism in all hematopoietic lineages [8,9]. Four
ITC-conditioned haplo-HCT recipients that did not
engraft and lost peripheral blood chimerism are dis-
cussed in this report. Cellular and humoral antidonor
MHC responses were studied before and after reexpo-
sure to donor antigen. Antidonor immune responses
were compared in HCT recipients and na€ıve animals
exposed to donor antigen. Our findings provide insight
into the immunologic responses after graft loss and
may serve as a guide for modifying preparatory regi-
mens when subsequent retransplantation of immune-
sensitized hosts is considered.MATERIALS AND METHODS
Animals
Animals were selected from our herd of MGH
MHC-defined miniature swine [10,11]. The donors
ranged in age from 4 to 8 months, and the recipients
were age 9-12 weeks and weighed 9-13 kg at the time
of HCT. Donor and recipients were chosen to differ
by 1MHChaplotype at bothMHC I andMHC II. Re-
cipients expressed swine leukocyte antigen (SLA)ad,
and donors expressed SLAac, hereinafter referred to
as AD and AC, respectively. To facilitate the detection
of chimerism, the donors were positive for pig allelic
antigen (PAA), a nonhistocompatibility cell surface an-
tigen present on all differentiated hematopoietic cells
in animals that express this gene allele [12]. The recip-
ients were PAA-negative.HCT Protocol
The HCT protocol consisted of a combination of
irradiation, T cell depletion, and hematopoietic cell
infusion from a single-haplotype MHC-mismatched
donor, with 45 days of cyclosporine cover for the
peri-infusion/postinfusion period. Serum cyclosporine
(CyA) levels weremaintained between 400 and 800 ng/
uL. T cell depletion was achieved using pCD3 immu-
notoxin (CD3-IT) [13] for 4 days before HCT. This
recombinant CD3 immunotoxin selectively binds por-
cine CD3 and contains a diphtheria toxin subunit,
which results in protein synthesis inhibition and deple-
tion of CD31 cells [14]. Animal 18862 did not receive
CD3-IT.
Donor animals were cytokine-mobilized for 5-7
days with recombinant porcine IL-3 and porcine
stem cell factor (Immerge Biotherapeutics, Cam-
bridge, MA), each at a dose of 0.1 mg/kg for the first
30 kg of body weight and 0.05 mg/kg for each addi-
tional kg, as reported previously [8]. Peripheral blood
mononuclear cells (PBMCs) were collected by leuka-pheresis (COBE BCT, Lakewood, CO) beginning on
the 5th day of cytokine therapy and continuing until
the target cell number was attained. After the initial
leukapheresis, 5-12  109 PBMCs per kg (total of 5-
12  1010 PBMCs, as animals averaged 10 kg in
weight) were infused i.v. daily. Enteral CyA (Sandim-
mune) was administered via a gastrostomy tube start-
ing at 1 day before mobilized PBMC infusion and
continuing for 45 days. CyA whole blood levels were
maintained at 400-800 ng/mL for the first 30 days be-
fore being tapered over the subsequent 15 days to 200
ng/mL, at which point CyA was discontinued.
Donor Antigen Exposure after HCT
Intravenous delivery of unselected PBMCs
Nonmobilized leukocytes were collected by leuka-
pheresis from the original hematopoietic cell donor
and then infused i.v. into the recipient at a normalized
dose (CD31T cells) to include 5  107 donor T cells/
kg of recipient body weight. Animals that underwent
HCT received a donor leukocyte infusion (DLI)
from the same HCT donor animal.
Subcutaneous PBMCs
Donor PBMCs were collected from donor whole
blood. Eighty million donor PBMCs were washed
with PBS and injected s.c. with a 19-gauge needle (in
the inguinal region) with or without complete
Freund’s adjuvant. Cells were suspended in a total vol-
ume of 5 mL PBS before injection. The animals that
underwent HCT were immunized with PBMCs from
the same donor.
Skin grafting
A vascularized skin flap [9] was transplanted from
the inguinal region of the donor and placed on the
neck of the recipient. The skin graft was monitored
daily for color, temperature, and texture change.
Assessment of Chimerism
PAA is expressed on hematopoietic cells from
PAA1 donor animals but not in PAA2 recipients. Pe-
ripheral blood, bone marrow, and thymic donor chi-
merism were assessed by flow cytometry (FACScan;
BD Biosciences, San Jose, CA), as described previously
[8,12,15]. The following swine-specific antibodies
were used: CD3e (898H2-6-15; mouse IgGaK) [16],
CD4 (74-12-4; mouse IgG2bK), CD8a (76-2-11;
mouse IgG2aK), CD172 (74-22-15; mouse IgG1K)
[17-20], CD5 [21], and PAA (1038H-10-9; IgMK),
For assessment of chimerism, PAA staining was used
to distinguish donor-origin and recipient-origin cells
[20]. Monocyte and granulocyte chimerism was deter-
mined by gating on CD1721 mononuclear cells and
granulocytes, respectively.
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Figure 1. (A) Groups 1 and 3 received the ITC preparatory regimen and 45 days of immunosuppression. Groups 1 and 2 received mobilized PBMCs at
a dose of 5-10 billion cells/kg. A DLI of 50 million Tc/Eq/kg was given to animals in groups 1 and 2 without immunosuppression coverage. Group 3 re-
ceived a skin graft 2 months after discontinuation of immunosuppression. (B) Donor-derived chimerism in animals 19138-19140 that received RIC (100
cGy TBI, 45 CyA, CD3 immunotoxin). Animal 18862 received 100 cGy TBI and 45 days of CyAwithout CD3 immunotoxin. Peripheral blood chimerism
was lost in animals 19139, 19140, and 18862 by day 80 and in animal 19138 by day 150. Percentage donor chimerism was measured by the PAA1marker
(y-axis). Days post-HCT is shown on the x-axis. Group 1 comprises animals 19138, 19139, 19140, and 18862; group 2 includes animals 19937 and 19938;
and group 3 includes animal 20312.
Biol Blood Marrow Transplant 18:1629-1637, 2012 1631Groft Loss in Haploidentical HCT Swine ModalMixed Lymphocyte Reaction and Cell-Mediated
Lymphotoxicity Assays
In primary mixed lymphocyte reaction (MLR), re-
sponders (4  105 cells) and stimulators (4  105 cells
irradiated with 25 Gy) were cultured together. The re-
sponders and stimulators were plated at 200 mL/well in
triplicate and incubated for 5 days at 37C in 5% CO2
and 100% humidity. Proliferation of responder cells
was assessed by measuring the uptake of H3 thymidine
after 5 hours of incubation. Cell-mediated lymphocy-
totoxicity (CML) assays were performed as described
previously [22]. In brief, CML tissue culture medium
included fetal porcine serum. The medium consisted
of basal DMEM (Life Technologies, Grand Island,
NY) supplemented with 6% serum replacement me-
dium (Sigma-Aldrich, St. Louis, MO). For both
CML andMLR assays, PBMCs from noninbred Yuca-
tan or Yorkshire pigs were used as third-party positivestimulators and targets. Stimulation indices were cal-
culated by dividing the average counts per minute de-
tected for a particular responder–stimulator pair by the
average counts per minute for the same responder
stimulated by self-stimulators.
Complement-Mediated Antibody-Dependent
Cellular Cytotoxicity Assay
Allogeneic cytotoxic antibodies to donor PBMCs
were detected by complement-mediated cytotoxic as-
says, as described previously [23,24]. In brief, target
cells were diluted to 5  106 cells/mL and suspended
inMedium 199 (Cellgro, Herndon, VA) supplemented
with 2% FCS. In 96-well U-bottom plates (Costar,
Cambridge, MA), 25 mL of the appropriate target cell
suspension was incubated with 25 mL of serum serially
diluted from 1:2 to 1:1024 or controls for 15minutes at
37C, followed by a second incubation with 25 mL of
Table 1. Summary of Cellular and Humoral Outcomes in Experimental Animals That Underwent HCTwith Immunosuppression
(Group 1), Animals That Received No Immunosuppression but Were Exposed to Donor Antigen (Group 2), and 1 Animal That
Received Both a Preparatory Regimen and Donor Antigen, but Not at the Same Time (Group 3)
Group Animal
RIC
Regimen HCT
First Antigen
Exposure
Antidonor
Antibodies
Sensitized
Antidonor
Cellular
Responses
Second
Antigen
Exposure
Antidonor
Antibodies
Sensitized
Antidonor
Cellular
Responses
Major Contributor to
Antidonor Response
(1) Experimental
HCT
19138
19139
19140
Yes Yes i.v. (at time of HCT) No No i.v. No Yes Sensitized cellular
alloresponses
18862 No antibody produced
after skin graft more
than 1 year after HCT
(2) Na€ıve, i.v. only 19937
19938
No Yes IV Yes No i.v. Yes No Alloantibody
(3) Conditioning
only (no HCT)
20312 Yes No Skin (after D/C CyA) Yes Yes ND ND ND Alloantibody and
sensitized cellular
alloresponses
ND indicates not done; D/C, discontinue.
1632 Biol Blood Marrow Transplant 18:1629-1637, 2012R. Duran-Struuck et al.appropriately diluted rabbit complement. Dead cells
were identified by staining with 10 mL of 7-AAD for
30 minutes. Data were acquired, and the percentage
of dead cells was assessed using a FACScan (BDBiosci-
ences) and analyzed with WinList analysis software
(Verity Software, Topsham, ME).RESULTS
In the current study, we investigated the immune
responses of animals that lost peripheral blood chime-
rism within 200 days of HCT (Figure 1 and Table 1).
Animals 19138-19140 underwent the same ITC regi-
men, whereas animal 18862 received a modified regi--10
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Figure 2. CML results before and after HCT in animals that lost their hemato
versus third party (diamonds) performed in animals that received a haplo-HCT
weeks after HCT.men without porcine CD3 immunotoxin consisting
of 45 days of CyA and 100 cGy of TBI at 2 days before
HCT. These 4 animals lost peripheral blood chime-
rism within 80 days (animals 19139, 19140, and
18862) and 150 days (animal 19138) after HCT. All as-
says performed assessed the response of PBMCs.
Antidonor Cellular Responses after Graft Loss
Are Comparable to Na€ıve Alloresponses
After graft loss (weeks 14-16), antidonor cellular
cytotoxic responses appeared similar to responses
seen before HCT (Figure 2A and B). MLRs were per-
formed to assess for evidence of cellular sensitization
in these animals. When animals are sensitized to19140
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Figure 3. Antidonor cellular proliferative responses after loss of donor hematopoietic cell graft. (A) Representative animal demonstrating early cellular
proliferative responses after exposure to donor antigen, suggestive of sensitization. Note the early proliferative responses (day 3). This animal (AD)
received 2 s.c. injections (1 month apart) of MHC-mismatched (AC) PBMCs without immunosuppression. (B) Representative responses of an AD animal
that was never exposed to donor AC antigen. Na€ıve animals exhibited maximal proliferative responses after 5 days, stimulation in culture. (C-E) Cellular
responses after graft loss in animals 19138 (C), 19139 (D), and 19140 (E). Assays were performed on week 33 (231 days post-HCT). Note the pattern
similarity to (B) but not to (A). The number on top of the bars are the stimulation index.
Biol Blood Marrow Transplant 18:1629-1637, 2012 1633Groft Loss in Haploidentical HCT Swine ModalMHC-mismatched donor antigen, proliferative re-
sponses are maximal after only 2 or 3 days of stimula-
tion, and by day 5 there is no (or minimal) further
proliferation based on thymidine uptake (Figure 3A
and B). In swine, normal alloproliferative responses
(without previous donor antigen exposure) across
MHC barriers are maximal after 5 days of stimulation
in vitro (Figure 3B). Early (day 3) and standard 5-day
proliferative responses of animals 19138-19140 to do-
nor MHC-matched PBMCs were assessed to deter-
mine whether the animals exhibited a pattern of
sensitization similar to that shown in Figure 3A.
Similar to animals not previously exposed to donor an-
tigen, the 4 animals that lost chimerism after ITC-
conditioned haplo-HCT showed maximal prolifera-
tion after 5 days of stimulation, with little to no
proliferation observed after 3 days of stimulation
(Figure 3C-E).
Lack of Antidonor Antibody Responses after
Graft Loss
We next examined whether antidonor antibody
was induced after haplo-HCT in ITC-conditioned an-imals that lost chimerism yet regained MLR responses
similar to a na€ıve animal. Serum from animals 19138-
19140 was assessed for the presence of alloantibodies
based on both binding and antibody-mediated cellular
cytotoxicity to donor cells. No serum antibody binding
to donor PBMCs was detected by flow cytometry (data
not shown). Using the more sensitive antibody-medi-
ated cellular cytotoxicity assay, we confirmed the ab-
sence of detectable antidonor antibodies in serum
(Figure 4A).
Sensitized Cellular Responses Observed before
and after Second Antigen Exposure via DLI
ITC-conditioned haplo-HCT recipients that lost
peripheral blood chimerism did not appear to be sen-
sitized to donorMHC, based on the lack of a detectable
alloantibody response. Cellular proliferative responses
to donor-matched PBMCs in these animals also ap-
peared similar to the response seen in a na€ıve animal
(not exposed to donor antigen). We next asked how
these animals with apparently na€ıve alloresponses after
haplo-HCT would react immunologically to another
exposure to donor cells. We hypothesized that
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Figure 4. Antidonor antibody assessment after HCT detected by complement-mediated antibody-dependent cellular cytotoxicity assay. (A) Serum
samples from recipient animals 19138-19140 (Table 1; group 1) after loss of the hematopoietic cell graft and peripheral blood chimerism. Serum samples
from animals 19138-19140 were analyzed before HCTand after loss of peripheral blood chimerism. The positive control serum used for the cytotoxic
assays comes from an AD pig that was grafted with a CC skin graft that was subsequently rejected within 7 days. On day121 after graft placement, this
control animal also received CC PBMCs s.c. (as a form of reimmunization). The target cells used in the antibody cytotoxicity assay were AC (donor type)
PBMCs. (B) Antibody cytotoxicity after a DLI and 2 injections (animals 19138 and 19139) or 1 injection (animal 19140) of donor AC PBMCs delivered s.c.
in an attempt to immunize the animals not developing alloantibodies (Figure 1A; group 1). (C) Antibody cytotoxicity responses of 2 animals (19937 and
19938) that did not receive immunosuppression after receipt of their first dose of donor antigen in the form of cytokine-mobilized PBMCs (Figure 1A;
group 2). As early as 1 week after i.v. immunization, animals 19937 and 19938 developed antidonor antibodies. (D) Animal 20312 received an RIC reg-
imen without antigen exposure (no HCT), to examine whether the preparatory regimen alone can prevent development of alloantibodies. At 2 months
after discontinuation of immunosuppression, animal 20312 received a donor skin graft, and antidonor antibodies were tested (Figure 1A; group 3).
1634 Biol Blood Marrow Transplant 18:1629-1637, 2012R. Duran-Struuck et al.reexposure to donor antigen would induce responses
similar to those observed in animals that had never
been exposed to donor antigen. Animals 19138-
19140 received their second antigen load i.v. in the
form of a DLI. Na€ıve (unexperimented) animals that
received PBMCs i.v. for the first time (and without im-
munosuppression) developed antidonor antibodies
(animals 19937 and 19938; Figure 4C). After the
DLI, animals 19138-19140 (who had lost their grafts)
still demonstrated no antidonor alloantibodies
(Figure 4B) despite exhibiting sensitized cellular pro-
liferative responses (Figure 5A) after the DLI. In con-
trast, animals 19937 and 19938 (healthy animals
without immunosuppression responding to a DLI) de-
veloped strong antidonor alloantibody responses while
retaining normal (day 5) proliferative responses
(Figure 5B and Table 1) to the donor after 2 i.v. infu-
sions of donor cells. These proliferative responses
were comparable to those seen in animals that had
never been exposed to donor antigen (Figure 5C).We ruled out the possibility that the preparatory
regimen could prevent the development of alloanti-
bodies. Animal 20312 (Figures 4D and 5C) underwent
the preparatory regimen and received donor antigen
(in the form of a skin graft) only after immunosuppres-
sion had been discontinued for 2 months. The effects
of the preparatory regimen did not prevent animal
20312 from developing humoral and cellular immune
responses when donor skin antigen was given at
2 months after immunosuppression.DISCUSSION
Animals that lost their HCT graft after ITC condi-
tioning regained normal cellular proliferative and cy-
totoxic alloresponses to the donor without any
detectable antidonor antibodies, similar to the allores-
ponses observed in animals that had never been ex-
posed to donor antigen. Given these results, animals
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Figure 5. Cellular responses after the second exposure to donor antigen. (A) SensitizedMLR assays in animals 19138-19140 in cells harvested on days 3
and 5. MLRs were performed at 1 month after the second exposure of donor antigen (DLI). (B) MLRs of animals 19937 and 19938, which received i.v.
PBMCs without immunosuppression. The third animal (na€ıve control) is an animal (from the farm) that was never exposed to donor antigen. The MLR of
the na€ıve control was performed in parallel to MLRs of animals 19937 and 19938. All 3 animals are of the same haplotype as the experimental HCT
recipients (animals 19138-19140). In brief, animals 19937 and 19938 received mobilized PBMCs without immunosuppression (antigen dose 1) and a sub-
sequent DLI (antigen dose 2), all at equal doses as those delivered to experimental HCTanimals. MLRs for animals 19937 and 19938were performed at 1
month after DLI (after the second i.v. sensitization of donor antigen). (C) Animal 20312 received the ITC regimen without exposure to donor antigen.
The MLR shown was performed at 1 month after a skin graft was placed (and rejected within 10 days). The graft was placed 2 months after discontin-
uation of immunosuppression. The number on top of the bars are the stimulation index.
Biol Blood Marrow Transplant 18:1629-1637, 2012 1635Groft Loss in Haploidentical HCT Swine Modalthat lost chimerismmight be expected to have immune
responses to DLI comparable to those seen in na€ıve
animals, but we have demonstrated that this assump-
tion was unfounded. A second donor antigen exposure
(without immunosuppression) in the form of a DLI in
animals that lost chimerism induced an early cellular
proliferative immune response different from that
seen in animals that received a similar antigenic expo-
sure without immunosuppression. Our findings do not
directly prove that initial exposure to donor cells in an-
imals that had lost their grafts induced an immune re-
sponse leading to graft loss. However, our cellular andhumoral assays indirectly suggest that this could be
a possibility.
A second remarkable, clinically relevant finding is
the observation that alloantibodies were never induced
after graft loss or after DLI in ITC-conditioned haplo-
HCT recipients. Antidonor alloantibodies are gener-
ally tested in the clinic to assess for sensitization
[25,26]. Our data suggest that the absence of alloanti-
bodies after graft loss might not be a reliable indicator
of a lack of sensitization, and that decisions regarding
retransplantation based on their presence may be mis-
guided. This scenario must not be confused with
1636 Biol Blood Marrow Transplant 18:1629-1637, 2012R. Duran-Struuck et al.patients who have been exposed to donor antigen be-
fore HCT (by, eg, transfusions) and who have already
developed alloantibodies beforeHCT.The swine ITC
HCT model is similar to transplantation scenarios in
which patients who lack antidonor antibodies before
HCT undergo RIC regimens and lose their donor he-
matopoietic cell graft. In these patients, the presence
or absence of alloantibody is used as a diagnostic tool
to assess the need for retransplantation.
The preparatory regimen might have had some
impact in the immunologic outcomes observed. We
previously reported that CD3-ITC delivered to ani-
mals that received the ITC regimen had a minimal im-
pact on the level of donor T cell chimerism [8]. All
animals that received the ITC regimen achieved stable
mixed chimerism [8,9]. Recipients received fewer
PBMCs (5-12  1010 cells instead of 15  1010 cells),
because leukopheresis had to be discontinued early.
The donors had an adverse response to the cytokines
injected for stem cell mobilization (data not shown).
It is possible that the delivery of a reduced (albeit still
relatively high) cell dose in this very mild conditioning
regimen, or the fact that the donors became sick, might
have been a factor in the loss of chimerism and engraft-
ment. Although our results are based on a relatively
small cohort of animals, our data suggest that donor
cells did not disappear passively and likely were re-
jected. The regain of antidonor cellular responses
was associated with graft loss in these animals. It is pos-
sible that the incomplete depletion of host T cells in
combination with a lower HCT dose might have
been contributing factors in donor graft rejection
[3,27,28].
Clinical implications extrapolated from these stud-
ies may affect decision making in patients requiring re-
transplantation. This may be important especially
when considering the same donor, as in parent-to-
child haplo-HCT [5]. On one hand, our results argue
for the use of aggressive T cell–specific immune sup-
pression (eg, anti-CD2 or antithymocyte globulin) to
avoid the effects of cellular-sensitized responses, espe-
cially after the observed cellular responses on second
antigen exposure. However, on the other hand, it can
be argued that mild immunosuppression (with, eg, cal-
cineurin inhibitors) could be sufficient, given that no
sensitized responses were elicited right after graft
loss. Further studies are needed to evaluate which of
these 2 clinical approaches would be best.
Although induced alloantibody responses and
early proliferative responses to donor cells are strong
indicators of sensitization, as demonstrated in humans
[29,30] and mice [31], our data indicate in a clinically
relevant large-animal model that lack of antidonor al-
loantibody production does not reliably predict a lack
of sensitization. These results in cases where sensitiza-
tion after graft loss cannot be confirmed based on an-
tibody or cellular responses suggest that immunesuppression and/or T cell depletion may be warranted
before retransplantation.
In conclusion, the present study confirms that an
absence of sensitized cellular and humoral immune re-
sponses after graft loss does not necessarily indicate
lack of immune response to donor cells. Our results
have important clinical implications, and identification
of better and more sensitive assays should be consid-
ered to identify sensitized patients before retransplan-
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